Last reviewed · How we verify
Cyclophosphamide and azathioprine — Competitive Intelligence Brief
phase 3
Immunosuppressive agents / Cytotoxic agents
Immunology / Rheumatology
Small molecule
Live · refreshed every 30 min
Target snapshot
Cyclophosphamide and azathioprine (Cyclophosphamide and azathioprine) — Assistance Publique - Hôpitaux de Paris. This combination uses cyclophosphamide as an alkylating agent and azathioprine as a purine antagonist to suppress immune cell proliferation and function.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cyclophosphamide and azathioprine TARGET | Cyclophosphamide and azathioprine | Assistance Publique - Hôpitaux de Paris | phase 3 | Immunosuppressive agents / Cytotoxic agents |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Immunosuppressive agents / Cytotoxic agents class)
- Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cyclophosphamide and azathioprine CI watch — RSS
- Cyclophosphamide and azathioprine CI watch — Atom
- Cyclophosphamide and azathioprine CI watch — JSON
- Cyclophosphamide and azathioprine alone — RSS
- Whole Immunosuppressive agents / Cytotoxic agents class — RSS
Cite this brief
Drug Landscape (2026). Cyclophosphamide and azathioprine — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclophosphamide-and-azathioprine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab